UNAIDS welcomes new study, backs anti-retroviral treatment

Image
Press Trust of India New York
Last Updated : Jun 14 2013 | 6:55 AM IST
The United Nations agency leading the global HIV/AIDS response today maintained its strong support for a combined approach to prevent new HIV infections among injecting drug users, while welcoming a new study of the positive impact of an antiretroviral medicine.
"Piece by piece scientific advances are paving the way to the end of the AIDS epidemic," said Michel Sidibe, Executive Director of the Joint UN Program on HIV/AIDS (UNAIDS), welcoming the findings that an antiretroviral, taken daily, can reduce the risk of HIV infection by nearly half in HIV-negative man and women who inject drugs.
"The full potential of antiretroviral therapy in keeping people alive and well and in preventing new HIV infections is becoming apparent," Sidibe added.
The new study conducted by the Thai Ministry of Public Health, the United States Centers for Disease Control and the Bangkok Metropolitan Administration, enrolled approximately 1,930 men and 482 women who were HIV-negative and who injected drugs in Bangkok.
It found that the men and women who took a daily dose of the antiretroviral medicine tenofovir as oral pre-exposure prophylaxis (PrEP) were 49 per cent less likely to become infected with HIV than the volunteers who took the placebo.
"The results of this study are important and if used effectively in HIV programming could have a significant impact in protecting people who inject drugs from becoming infected with HIV,' Mr. Sidibe noted. The latest study complements results from several PrEP trials released over the past few years.
He stressed, however, that UNAIDS does not believe that a single intervention is completely protective in preventing HIV transmission, and supports combination harm reduction measures, such as provision of clean needles and syringes, opioid substitution therapy, accessible health care services together with the removal of punitive laws and collaboration with police and law enforcement strategies have proved effective in preventing new HIV infections among people who inject drugs.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 14 2013 | 6:55 AM IST

Next Story